Iressa Use Should Not Be Limited By EGFR Mutation Testing, Researchers Say
Executive Summary
Data suggesting that the efficacy of Iressa is associated with an EGFR gene mutation should not stem use of anti-EGFR agents in mutation-negative patients, researchers said